MEI Pharma Inc (MEIP)
MEI Pharma is a clinical-stage pharmaceutical company focused on developing cancer therapies. Co.'s drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.
Company Name: |
MEI Pharma Inc |
Website: |
www.meipharma.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding MEIP: |
3 |
Total Market Value Held by ETFs: |
$943930 |
Total Market Capitalization: |
$22.00M |
% of Market Cap. Held by ETFs: |
4.29% |
|
|
April 17, 2024 2:33 PM Eastern
Buy (3.00 out of 4)
100th percentile
|
|